医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZS Genetics, Inc. and Hitachi High Technologies America, Inc. Enter Strategic Product Development Collaboration for Commercialization of a Unique Third-Generation, Single-Molecule DNA Sequencing Platform

2017年03月08日 PM10:00
このエントリーをはてなブックマークに追加


 

WAKEFIELD, Mass. & CLARKSBURG, Md.

ZS Genetics, Inc. and Hitachi High Technologies America, Inc. (HTA) announced today a strategic collaboration to develop and commercialize ZS Genetics’ DNA sequencing platform. ZS Genetics’ proprietary technologies, based on high-resolution electron microscopy (EM), will allow the scientific community for the first time to sequence very high-quality long reads (50,000+ base-pairs) of single DNA molecules. The scientific value of very long-read, single-molecule DNA sequencing has been an imperative for many years to more fully address the industry’s critical work across the most complex diseases, as well as novel genomic discovery initiatives.

“The rapidly increasing complexity of scientific discovery continues to reinforce the need for higher quality and more scientifically rich DNA sequencing capabilities,” said ZS Genetics’ Chief Executive Officer, John A. McCarthy, Jr. “The technical capabilities of our two companies are expected to produce a DNA sequencing platform capable of enabling unique scientific discovery, as well as offering a powerful tool to complement and broaden current short-read sequencing technologies. Combining ZS Genetics’ proprietary long-read technologies with HTA’s leadership in high-resolution EM is expected to accelerate the introduction of this important technology into leading scientific institutions.”

“We are very pleased to be collaborating with ZS Genetics and their broad team of industry thought leaders to accelerate the introduction of this unique and powerful application of high-resolution EM into the scientific community,” stated Phil Bryson, Vice President and General Manager of HTA’s Nanotechnology Systems Division. “We are confident that HTA’s decades-long leadership in high-resolution EM for highly complex applications in R&D and industry can translate readily into this powerful and important new application for the life sciences industry.”

ZS Genetics plans to initiate an early-access center in its Wakefield, Massachusetts facility later in 2017 for product and application development in collaboration with select customer and supply-chain partners. Other details and terms of the strategic product development relationship between ZS Genetics and HTA are not being disclosed.

About ZS Genetics, Inc.

ZS Genetics, Inc. is a privately held Massachusetts company focused on developing and commercializing a unique “Third-Generation” DNA sequencing technology platform for the global scientific community. The Company’s technology platform combines state-of-the-art, high-resolution electron microscopy with proprietary DNA sample preparation to generate very long-read (50,000+ base-pairs), high-quality, single-molecule DNA sequence information. ZS Genetics’ sequencing platform is expected to enable unique scientific discovery across the world’s most complex diseases, accelerate critical areas of novel scientific discovery, and complement in a very powerful manner existing short-read DNA sequencing technologies.

About Hitachi High Technologies America, Inc.

Hitachi High Technologies America, Inc., a subsidiary of Hitachi High-Technologies Corporation, is a privately owned global affiliate company that operates within the Hitachi Group Companies. HTA sells and services semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products, as well as industrial equipment, electronic devices, and electronic and industrial materials.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170308005430/en/

CONTACT

ZS Genetics, Inc.
John A. McCarthy, Jr.
Chief Executive Officer
jam@zsgenetics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories Announces the Launch of Progesterone Capsules in the U.S. Market
  • シネクサス、世界をリードする治験実施施設ネットワークとしての能力を強化
  • Synexus提升能力成为世界领先的研究单位网络
  • Replicor披露 NAP功能性控制HBV和HDV的1年成果及有关NAP药理机制的新见解
  • ReplicorがNAPによるHBV/HDVの1年間の機能的制御の達成とNAPの薬理作用機序に関する新知見を公表